ดูเหมือนว่ามีข้อผิดพลาดเกิดขึ้นขณะกำลังโหลดหน้าเพจนี้.
ทีมงานของเราได้รับแจ้งแล้วแต่กรุณาติดต่อเราด้วยการใช้ วิจิทบริการสนับสนุนทางอีเมล หากปัญหายังคงมีอยู่
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Revenue Multiple | 6.4x - 7.1x | 6.7x |
| Selected Fwd Revenue Multiple | 4.3x - 4.7x | 4.5x |
| Fair Value | ¥27.57 - ¥29.98 | ¥28.78 |
| Upside | 13.1% - 23.0% | 18.1% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Mabwell (Shanghai) Bioscience Co., Ltd. | 688062 | SHSE:688062 |
| Staidson (Beijing) BioPharmaceuticals Co., Ltd. | 300204 | SZSE:300204 |
| Shanghai Kehua Bio-Engineering Co.,Ltd | 2022 | SZSE:002022 |
| Shanghai Henlius Biotech, Inc. | 2696 | SEHK:2696 |
| Mabpharm Limited | 2181 | SEHK:2181 |
| Nanjing Vazyme Biotech Co., Ltd | 688105 | SHSE:688105 |
| Select LTM Revenue Multiple | ||||||||
| Benchmark Companies | ||||||||
| 688062 | 300204 | 2022 | 2696 | 2181 | 688105 | |||
| SHSE:688062 | SZSE:300204 | SZSE:002022 | SEHK:2696 | SEHK:2181 | SHSE:688105 | |||
| Historical Revenue Growth | ||||||||
| 5Y CAGR | 46.5% | -13.3% | 4.1% | 129.0% | 78.9% | 38.6% | ||
| 3Y CAGR | 130.5% | -17.8% | -16.4% | 50.4% | 46.1% | -9.8% | ||
| Latest Twelve Months | 55.5% | -10.8% | -46.3% | 6.1% | 196.3% | 6.6% | ||
| Historical EBIT Profit Margin | ||||||||
| 5 Year Average Margin | -3248.0% | -47.0% | 18.9% | -92.3% | -656.3% | 14.1% | ||
| Prior Fiscal Year | -853.4% | -102.6% | 30.4% | 11.7% | -231.7% | -21.1% | ||
| Latest Fiscal Year | -536.3% | -10.5% | -5.8% | 15.1% | -46.3% | -4.6% | ||
| Latest Twelve Months | -536.3% | -10.5% | -18.1% | 15.1% | -46.3% | -4.6% | ||
| Current Trading Multiples | ||||||||
| EV / LTM Revenue | 43.97x | 9.00x | 1.68x | 3.56x | 10.40x | 5.66x | ||
| EV / LTM EBIT | -8.2x | -85.6x | -9.3x | 23.5x | -22.4x | -122.0x | ||
| Price / LTM Sales | 41.03x | 10.69x | 1.56x | 3.07x | 9.54x | 6.99x | ||
| Low | Mid | High | ||||||
| Benchmark EV / LTM Revenue | 1.68x | 9.00x | 43.97x | |||||
| Historical EV / LTM Revenue | 5.00x | 6.10x | 24.13x | |||||
| Selected EV / LTM Revenue | 6.40x | 6.74x | 7.08x | |||||
| (x) LTM Revenue | 1,371 | 1,371 | 1,371 | |||||
| (=) Implied Enterprise Value | 8,776 | 9,238 | 9,700 | |||||
| (-) Non-shareholder Claims * | 1,815 | 1,815 | 1,815 | |||||
| (=) Equity Value | 10,591 | 11,053 | 11,515 | |||||
| (/) Shares Outstanding | 393.0 | 393.0 | 393.0 | |||||
| Implied Value Range | 26.95 | 28.12 | 29.30 | |||||
| FX Rate: CNY/CNY | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 26.95 | 28.12 | 29.30 | 24.37 | ||||
| Upside / (Downside) | 10.6% | 15.4% | 20.2% | |||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | 688062 | 300204 | 2022 | 2696 | 2181 | 688105 | |
| Enterprise Value | 8,753 | 2,923 | 3,129 | 20,418 | 2,687 | 7,763 | |
| (+) Cash & Short Term Investments | 1,585 | 54 | 1,024 | 814 | 89 | 2,475 | |
| (+) Investments & Other | 0 | 514 | 27 | 0 | 0 | 0 | |
| (-) Debt | (2,182) | (30) | (433) | (3,648) | (312) | (660) | |
| (-) Other Liabilities | 0 | 12 | (822) | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 8,156 | 3,473 | 2,924 | 17,584 | 2,464 | 9,578 | |
| (/) Shares Outstanding | 399.6 | 477.8 | 501.6 | 543.5 | 4,124.1 | 393.0 | |
| Implied Stock Price | 20.41 | 7.27 | 5.83 | 32.35 | 0.60 | 24.37 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 0.93 | 0.93 | 1.00 | |
| Implied Stock Price (Trading Cur) | 20.41 | 7.27 | 5.83 | 34.65 | 0.64 | 24.37 | |
| Trading Currency | CNY | CNY | CNY | HKD | HKD | CNY | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 0.93 | 0.93 | 1.00 | |